Aromasin (exemestane) Shows Some Advantages Over Tamoxifen As Adjuvant Therapy In Early Breast Cancer; First Results Of The TEAM Trial

Interim findings of the TEAM (Tamoxifen Exemestane Adjuvant Multicenter) trial reported on 11th December at the 2008 San Antonio Breast Cancer Symposium (SABCS) suggest women with early invasive breast cancer can expect fewer breast cancer recurrences and a longer time to the occurrence of distan

More: continued here

Filed under: Breast Cancer on December 19th, 2008